MedTrace Logo

A Short-contact Plaque Test Study With Daivobet® Gel in Psoriasis Vulgaris

NCT01607853 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-03-10

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the anti-psoriatic effect of Daivobet® gel applied then removed after 10 minutes (+/- 2 minutes), Daivobet® gel applied then removed after 20 minutes (+/- 2 minutes) compared with Daivobet® gel and Daivobet® gel vehicle applied for 24 hours (+/- 2 hours), using the psoriasis plaque test modified from the method developed by KJ Dumas and JR Scholtz.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

Daivobet® gel applied then removed after 10 minutes (+/- 2 minutes)

Once daily application, 3 weeks

DRUG

Daivobet® gel applied then removed after 20 minutes (+/- 2 minutes)

Once daily application, 3 weeks

DRUG

Daivobet® gel applied for 24 hours (+/- 2 hours)

Once daily application, 3 weeks

DRUG

Daivobet® gel vehicle applied for 24 hours (+/- 2 hours)

Once daily application, 3 weeks

Sponsors & Collaborators

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • Catherine Queille-Roussel, MD · Centre de Pharmacologie Clinique Appliquée à la Dermatologie (CPCAD), Hôpital l'Archet 2, 151 route Saint-Antoine de Ginestière 06202 Nice Cedex 3, France

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01607853 on ClinicalTrials.gov